遗传风险评分在1型糖尿病中的应用价值
综述指出,1型糖尿病遗传学已识别超过70个风险区域,其中HLA II类区域关联最强,可解释超过50%的遗传度。多基因评分整合风险变异为单一数值,在糖尿病分型鉴别及新生儿筛查中具有应用价值,但非欧洲人群数据缺乏及临床整合指南不足是主要障碍。
要点
- 1型糖尿病遗传风险评分有助于区分1型糖尿病、2型糖尿病与MODY。
- 新生儿筛查研究利用1型糖尿病遗传风险评分识别未来发病风险婴儿。
- 非欧洲人群大型病例对照队列缺乏,限制跨祖先遗传风险评分的准确性。
核心结论
- 1型糖尿病遗传风险评分在糖尿病分型鉴别和新生儿筛查中有应用价值,但临床实施受限于缺乏与其他生物标志物及临床变量整合的指南和知识。
研究设计与样本
- 综述性文章,未报告系统检索范围与样本量。
主要发现
- 1型糖尿病遗传学已识别超过70个与疾病风险相关的遗传区域,其中HLA II类区域强关联可解释超过50%的遗传度。
- 多基因风险评分纳入全基因组许多可能相关变异,即使未达全基因组显著性;遗传风险评分估计达到全基因组显著性的较小遗传变异子集的累积贡献。
- 1型糖尿病遗传风险评分在糖尿病分型中有助于区分1型糖尿病、2型糖尿病和MODY。
- 1型糖尿病遗传风险评分正用于新生儿筛查研究,以识别未来发病风险婴儿。
- 多数早期1型糖尿病遗传学研究在欧洲血统人群中进行,需非欧洲人群大型病例对照队列以开发跨多样血统的准确遗传风险评分。
关键数值与推荐
- 1型糖尿病遗传风险评分有助于区分1型糖尿病、2型糖尿病和MODY。
- 1型糖尿病遗传风险评分用于新生儿筛查研究识别未来发病风险婴儿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数早期1型糖尿病遗传学研究在欧洲血统人群中进行。
- 需非欧洲人群大型病例对照队列以开发跨多样血统的准确遗传风险评分。
- 遗传风险评分临床实施的当前障碍主要与缺乏与其他生物标志物及临床变量整合的指南和知识有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iterative advances in understanding of the genetics of type 1 diabetes have identified >70 genetic regions associated with risk of the disease, including strong associations across the HLA class II region that account for >50% of heritability. The increased availability of genetic data combined with the decreased costs of generating these data, have facilitated the development of polygenic scores that aggregate risk variants from associated loci into a single number: either a genetic risk score (GRS) or a polygenic risk score (PRS). PRSs incorporate the risk of many possibly correlated variants from across the genome, even if they do not reach genome-wide significance, whereas GRSs estimate the cumulative contribution of a smaller subset of genetic variants that reach genome-wide significance. Type 1 diabetes GRSs have utility in diabetes classification, aiding discrimination between type 1 diabetes, type 2 diabetes and MODY. Type 1 diabetes GRSs are also being used in newborn screening studies to identify infants at risk of future presentation of the disease. Most early studies of type 1 diabetes genetics have been conducted in European ancestry populations, but, to develop accurate GRSs across diverse ancestries, large case-control cohorts from non-European populations are still needed. The current barriers to GRS implementation within healthcare are mainly related to a lack of guidance and knowledge on integration with other biomarkers and clinical variables. Once these limitations are addressed, there is huge potential for 'test and treat' approaches to be used to tailor care for individuals with type 1 diabetes.
引用
- Luckett AM, Weedon MN, Hawkes G, et al. Utility of genetic risk scores in type 1 diabetes. Diabetologia. 2023. PMID: 37439792. doi:10.1007/s00125-023-05955-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。